And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine ... prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling ...

New drug approvals and strong pipeline progress are likely to help ... it through our "Recent Price Strength" screen. Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective ...

Another pipeline program is addressing Sjogren ... largely due to product sales of Ohtuvayre. Secondly, the company’s strategic projects like Ensifentrine hold future potential for investors.

Looking beyond the current success of Ohtuvayre's launch, Truist Securities is also anticipating updates throughout 2025 regarding Verona Pharma's pipeline. These updates are expected to include ...

Looking beyond the current success of Ohtuvayre's launch, Truist Securities is also anticipating updates throughout 2025 regarding Verona Pharma's pipeline. These updates are expected to include ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...